Three Cases with L1 Syndrome and Two Novel Mutations in the L1CAM Gene

Total Page:16

File Type:pdf, Size:1020Kb

Three Cases with L1 Syndrome and Two Novel Mutations in the L1CAM Gene Eur J Pediatr DOI 10.1007/s00431-015-2560-2 SHORT COMMUNICATION Three cases with L1 syndrome and two novel mutations in the L1CAM gene Rosario Marín1 & Miriam Ley-Martos3 & Gema Gutiérrez4 & Felicidad Rodríguez-Sánchez5 & Diego Arroyo6 & Francisco Mora-López2 Received: 28 October 2014 /Revised: 24 April 2015 /Accepted: 27 April 2015 # Springer-Verlag Berlin Heidelberg 2015 Abstract Mutations in the L1CAM gene have been identified are currently considered different phenotypes of a single entity in the following various X-linked neurological disorders: con- known as L1 syndrome. We present three families with L1 genital hydrocephalus; mental retardation, aphasia, shuffling syndrome. Sequencing of the L1CAM gene allowed the iden- gait, and adducted thumbs (MASA) syndrome; spastic para- tification of the following mutations involved: a known splic- plegia; and agenesis of the corpus callosum. These conditions ing mutation (c.3531-12G>A) and two novel ones: a missense mutation (c.1754A>C; p.Asp585Ala) and a nonsense muta- tion (c.3478C>T; p.Gln1160Stop). The number of affected Communicated by Beat Steinmann males and carrier females identified in a relatively small pop- Revisions received: 14 March 2015/23 March 2015/21 April 2015/24 ulation suggests that L1 syndrome may be under-diagnosed. April 2015 Conclusion: L1 syndrome should be considered in the dif- ferential diagnosis of intellectual disability or mental retarda- * Francisco Mora-López tion in children, especially when other signs such as hydro- [email protected] cephalus or adducted thumbs are present. Rosario Marín [email protected] What is Known: Miriam Ley-Martos • Mutations in L1CAM have been identified in various X-linked recessive [email protected] neurological disorders. Gema Gutiérrez • L1CAM mutations are a cause of intellectual disability in children. [email protected] What is New: • Felicidad Rodríguez-Sánchez L1 syndrome should be considered in the differential diagnosis of [email protected] intellectual disability in children. • We describe three families with L1 syndrome, and we report two Diego Arroyo previously undescribed L1CAM mutations. [email protected] 1 Clinical Genetics Unit, Hospital Universitario Puerta del Mar, Keywords L1 syndrome . L1CAM . X-linked mental Cádiz, Spain retardation . Adducted thumbs . X-linked hydrocephalus 2 Molecular Diagnosis Laboratory, Immunology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain 3 Department of Paediatrics, Hospital Universitario Puerta del Mar, Cádiz, Spain Abbreviations 4 Department of Paediatrics, Hospital Universitario de Jerez, L1CAM L1 cell adhesion molecule Jerez, Spain MRI Magnetic resonance imaging 5 Division of Genetics, Human Anatomy Department, Universidad de MASA syndrome Mental retardation, aphasia, Cádiz, Cádiz, Spain shuffling gait, and adducted 6 Progenie molecular S. L. Laboratory, Valencia, Spain thumbs syndrome Eur J Pediatr Introduction The sequence of L1CAM gene showed an A>C substitution at the nucleotide 1754 (c.1754 A>C) involving the replace- Mutations in the gene encoding the L1 cell adhesion molecule ment of an aspartic acid in position 585 by an alanine in the (L1CAM) cause a wide phenotypic spectrum syndrome asso- extracellular domain of the protein (p.Asp585Ala). The muta- ciated with hydrocephalus, developmental delay, and brain tion was inherited from the mother. This missense variant has malformation [7]. The syndrome is a manifestation of an X- not been previously reported. linked recessive disorder. The term L1 syndrome includes hydrocephalus due to congenital stenosis of the aqueduct of Case 3 Sylvius (OMIM #307000), mental retardation, aphasia, shuf- fling gait, and adducted thumbs (MASA) syndrome (OMIM A 2-year-old boy with psychomotor developmental delay was #303350), X-linked complicated hereditary spastic paraplegia referred to our department. He was the only child of healthy, type 1 (OMIM #303350), and X-linked agenesis of the corpus non-consanguineous parents. He had no relatives with a he- callosum (OMIM #304100). L1CAM plays an important role reditary disease or mental retardation. He showed bilateral in the development of the central nervous system where it is adducted thumbs. Brain MRI revealed corpus callosum agen- involved in neuronal migration and differentiation as well as esis. At 4 years of age, he presented spastic paraplegia. in complex cognitive and memory processes. LICAM gene sequence analysis detected a C>T base substitu- tion (c.3478 C>T). This change produces the replacement of glutamine at codon 1160 with a stop signal (p.Gln1160Stop) Case reports yielding a truncated protein, which loses the 97 carboxyl- terminal amino acids. To our knowledge, this variant has not Case 1 been previously reported. Since the mother is not a carrier of this variant as judged by a DNA analysis of peripheral leuko- A 5-year-old boy was referred to the medical genetics depart- cytes, it is probably arisen de novo. ment. He was the first child of a healthy and non- consanguineous couple. He presented developmental delay, bilaterally flexed adducted thumbs, and bilateral clinodactyly Molecular analysis of the fifth finger (Fig. 1a). He did not present dysmorphic facial features. Prenatal ultrasound findings in the third trimes- Genomic DNA was extracted from peripheral leukocytes ac- ter had revealed congenital hydrocephalus. At birth, a cording to standard protocols from patients and their relatives. transfontanellar ultrasound examination had shown enlarged Analysis of the L1CAM gene was performed by Sanger se- lateral ventricles and corpus callosum agenesis. Nuclear mag- quencing of all coding exons. In order to exclude the possi- netic resonance on the sixth day of life confirmed these find- bility that the new variants detected were rare polymorphisms, ings (Fig. 1b). A family history suggested X-linked recessive we tested for their presence in 100 healthy subjects. mental retardation (Fig. 1c). One maternal granduncle had mental retardation and adducted thumbs without other signs of the disease. Another affected member of the family died Discussion without a clinical or genetic diagnosis. Nowadays, at 12 years old, our patient shows adducted thumbs, mild mental retarda- L1 syndrome shows an extremely variable presentation within tion, microcephaly, and behavioral alterations. Direct se- and between families. The most consistent clinical signs in L1 quencing of the L1CAM gene detected a single-base substitu- syndrome are variable degrees of mental retardation, hydro- tion located 12 base pairs upstream of the exon 27 (c.3531- cephalus with varying degrees of severity, spasticity of lower 12G>A). The mutation was also detected in the mother and in limbs, and flexion deformity of the thumbs. In the central the maternal granduncle. nervous system, the most frequent pathological findings are the complete or partial absence of the corpus callosum and the Case 2 bilateral absence of the pyramidal tracts. Hypoplasia of the corpus callosum may contribute to mental retardation, where- A healthy, non-consanguineous couple was referred for genet- as the absence of the pyramidal tracts explains the spasticity ic counseling because of a family history of mental retardation observed in the patients. We report three cases of the disease. (Fig. 1d). Although the male partner did not display any of the Sequencing of the L1CAM gene in the three index cases clinical findings associated with L1 syndrome, he has two allowed us to identify three mutations, two of which had never brothers with intellectual disability. He also has three healthy been reported before. sisters; all have male sons with clinical signs of L1 syndrome: Patient 1 carried a splicing mutation (c.3531-12G>A). This hydrocephalus, developmental delay, and adducted thumbs. mutation has been previously described and affects the Eur J Pediatr Fig. 1 a Case 1: hands showing adducted thumbs. b Case 1: brain MRI, coronal view showing the left (L) lateral ventricle larger than the right (R) lateral ventricle. c, d Pedigrees of cases 1 and 2, respectively. Persons molecularly examined are indicated by an asterisk cytoplasmic domain of the protein, a well-conserved region in frameshift mutations that produce a premature stop codon L1-like proteins. It contains an amino acid sequence with a leading to truncation in extracellular domains or abolishing high affinity for ankyrin, a molecule that acts as a linker be- expression of the protein produce the most severe form of tween L1-like proteins and the cellular cytoskeleton [5]. The the syndrome, usually with severe congenital hydrocephalus mutation would produce a truncated cytoplasmic domain and early mortality. Missense mutations affecting the extracel- lacking this ankyrin-binding motif. It has been previously de- lular domain and mutations affecting only the cytoplasmic scribed in a patient diagnosed with MASA syndrome [6]and domain tend to cause milder phenotypes, usually found in has also been found in another family with nine males show- patients described as having MASA syndrome. In this study, ing mental retardation and adducted thumbs [4]. Our patient two of the mutations detected truncate only the cytoplasmic showed similar clinical features and severity. domain of the protein and the third one was a missense muta- A first novel missense mutation (c.1754 A>C; tion located in the extracellular domain. In the three reported p.Asp585Ala) was identified in affected males and female cases, we observed
Recommended publications
  • CRASH Syndrome: Clinical Spectrum Vance Lemmon0 Guy Van Campa of Corpus Callosum Hypoplasia, Lieve Vitsa Retardation, Adducted Thumbs, Paul Couckea Patrick J
    Review 1608178 Eur J Hum Genet 1995;3:273-284 Erik Fransen3' CRASH Syndrome: Clinical Spectrum Vance Lemmon0 Guy Van Campa of Corpus Callosum Hypoplasia, Lieve Vitsa Retardation, Adducted Thumbs, Paul Couckea Patrick J. Willemsa Spastic Paraparesis and a Department of Medical Genetics, Hydrocephalus Due to Mutations in University of Antwerp, Belgium; One Single Gene, L1 b Case Western Reserve University, Cleveland, Ohio, USA Keywords Abstract X-linked disorder LI is a neuronal cell adhesion molecule with important func­ Mental retardation tions in the development of the nervous system. The gene Hydrocephalus encoding LI is located near the telomere of the long arm of the MASA syndrome X chromosome in Xq28. We review here the evidence that Adducted thumbs several X-linked mental retardation syndromes including X- Corpus callosum agenesis linked hydrocephalus (HSAS), MASA syndrome, X-linked Spastic paraplegia complicated spastic paraparesis (SPI) and X-linked corpus LI callosum agenesis (ACC) are all due to mutations in the LI CRASH gene. The inter- and intrafamilial variability in families with Mutation analysis an LI mutation is very wide, and patients with HSAS, MASA, SPI and ACC can be present within the same family. There­ fore, we propose here to refer to this clinical syndrome with the acronym CRASH, for Corpus callosum hypoplasia, Retar­ dation, Adducted thumbs, Spastic paraplegia and Hydroceph­ alus. Clinical Aspects for Hydrocephalus due to Stenosis of the Aqueduct of Sylvius. This designation was X-Linked Hydrocephalus based upon the presence of aqueductal steno­ X-linked hydrocephalus (MIM No. sis in many HSAS patients [1]. However, later 307000) was originally described by Bickers studies reported several HSAS patients with and Adams in 1949.
    [Show full text]
  • Hereditary Spastic Paraparesis: a Review of New Developments
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.69.2.150 on 1 August 2000. Downloaded from 150 J Neurol Neurosurg Psychiatry 2000;69:150–160 REVIEW Hereditary spastic paraparesis: a review of new developments CJ McDermott, K White, K Bushby, PJ Shaw Hereditary spastic paraparesis (HSP) or the reditary spastic paraparesis will no doubt Strümpell-Lorrain syndrome is the name given provide a more useful and relevant classifi- to a heterogeneous group of inherited disorders cation. in which the main clinical feature is progressive lower limb spasticity. Before the advent of Epidemiology molecular genetic studies into these disorders, The prevalence of HSP varies in diVerent several classifications had been proposed, studies. Such variation is probably due to a based on the mode of inheritance, the age of combination of diVering diagnostic criteria, onset of symptoms, and the presence or other- variable epidemiological methodology, and wise of additional clinical features. Families geographical factors. Some studies in which with autosomal dominant, autosomal recessive, similar criteria and methods were employed and X-linked inheritance have been described. found the prevalance of HSP/100 000 to be 2.7 in Molise Italy, 4.3 in Valle d’Aosta Italy, and 10–12 Historical aspects 2.0 in Portugal. These studies employed the In 1880 Strümpell published what is consid- diagnostic criteria suggested by Harding and ered to be the first clear description of HSP.He utilised all health institutions and various reported a family in which two brothers were health care professionals in ascertaining cases aVected by spastic paraplegia. The father was from the specific region.
    [Show full text]
  • MASA Syndrome in Twin Brothers: Case Report of Sixteen-Year Clinical Follow Up
    Paediatr Croat. 2014;58:286-90 PRIKAZ BOLESNIKA / CASE REPORT www.paedcro.com http://dx.doi.org/10.13112/PC.2014.50 MASA syndrome in twin brothers: case report of sixteen-year clinical follow up Matilda Kovač Šižgorić1, Zlatko Sabol1, Filip Sabol2, Tonći Grmoja3, Svjetlana Bela Klancir1, Zdravka Gjergja1, Ljiljana Kipke Sabol1 MASA syndrome (OMIM 303350) is a rare X-linked recessive neurologic disorder, also called CRASH syndrome, spastic paraplegia 1 and Gareis-Mason syndrome. The acronym MASA describes four major signs: Mental retardation, Aphasia, Shuffl ing gait and Adducted thumbs. A more suitable name for this syndrome is L1 syndrome because the disorder has been associated with mutations in the neuronal cell adhesion molecule L1 (L1CAM) gene. The syndrome has severe symptoms in males, while females are carriers because only one X chromosome is aff ected. The aim of this report is to show similarities and diff erences in clinical manifestations between twins with the L1CAM gene mutation and to emphasize the importance of genetic counseling. Our patients were dizygotic twins born prematurely at 35 weeks of gestation. Pregnancy was complicated with early bleeding and gestational diabetes. Immediately after birth, hypertonia of lower extremities was observed in both twins. Sixteen-year clinical follow up showed spastic paraparetic form with shuffl ing gait, clumsiness, delayed speech development, lower intellectual functioning at the level of mild to moderate mental retarda- tion, primary nocturnal enuresis, behavioral and sleep disorder (more pronounced in the second twin). Magnetic resonance imaging of the brain showed complete agenesis of the corpus callosum, complete lack of the anterior commissure, and internal hydrocephalus.
    [Show full text]
  • Hirschsprung Disease in an Infant with L1 Syndrome
    Hirschsprung Disease in an Infant with L1 Syndrome: Report of a New Case and a Novel L1CAM Variant Teresa Andreone1 1Saint Louis University Care - The Physicians of Saint Louis University October 27, 2020 Abstract L1 syndrome is an X-linked disorder manifesting with congenital hydrocephalus, adducted thumbs and spasticity. There are rare cases of L1 syndrome and coincident Hirschsprung disease, with mutations in the L1CAM gene thought to underlie both. We present a novel pathogenic L1CAM variant in someone with L1 syndrome and Hirschsprung disease. Introduction The L1CAM gene encodes the membrane glycoprotein L1CAM, a calcium-independent cellular adhesion molecule involved in neuronal development. The L1CAM cell adhesion molecule is found on the X chromo- some in humans (and other mammals) and has a 1253 amino acid protein sequence. The extracellular portion is comprised of six immunoglobulin domains followed by five fibronectin type III domains which are con- nected to a small intracellular domain by a transmembrane helix (Figure 1). Mutations in theL1CAM gene cause L1 syndrome, which encompasses a spectrum of disease that includes four major X-linked conditions: X-linked congenital hydrocephalus due to stenosis of the aqueduct of Sylvius (HSAS; OMIM #307000); men- tal retardation, aphasia, shuffling gait and adducted thumbs syndrome (MASA; OMIM #303350); X-linked complicated hereditary spastic paraplegia type 1 (SPG1; OMIM#303350); and X-linked complicated agene- sis of the corpus callosum (OMIM #304100)1. More than 220 disease-causing variants in the L1CAM gene have been identified as causing the four major phenotypes of L1 syndrome2. Additionally, there are reports suggesting that additional mutations in L1CAM can cause mild behavioral and intellectual impairment3.
    [Show full text]
  • University of Groningen Genetics of L1 Syndrome Vos, Yvonne Johanna
    University of Groningen Genetics of L1 syndrome Vos, Yvonne Johanna IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2010 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Vos, Y. J. (2010). Genetics of L1 syndrome. [S.n.]. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 26-09-2021 Genetics Ll Syndr Yvonne Vos , ' Genetics of Ll syndrome Yvonne Johanna Vos Vos, Yvonne J Genetics of Ll syndrome Proefschrift Groningen ISBN: 978-90-367-4471-3 © Copyright 2010 Y.J. Vos All rights are reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmittedin any form or by any means, without permission of the author. Cover: Bob Vos Lay-out: Helga de Graaf, Studio Eye Candy, Groningen (www.proefschrift.info) Printed by lpskamp Drukkers, Enschede Stellingen behorende bij het proefschrift Genetics of Ll syndrome -·-····· ---· ·· -�--;.
    [Show full text]
  • GENETIC TESTING REQUISITION Please Ship All
    GENETIC TESTING REQUISITION 1-844-363-4357· [email protected] Schillingallee 68 · 18057 Rostock Germany Attention Patient: Please visit your nearest LifeLabs or CML Healthcare Patient Service Centre for sample collection LL: K012-01/ CML: CEN CONTRACT # Report to Physician Billing # LifeLabs Demographic Ordering Physician Name Label Physician Signature: Ordering Physician Address: Tel: Fax: Address & Contact Info: Copy to (name & contact info): Name: Contact: Bill to Contract # K012-01 (patient does not pay at time of collection) Patient Gender: (M/F) Patient Name (Last, First): Patient DOB: (YYYY/MM/DD) Patient Address: Patient Health Card: Patient Telephone: Please ship all NON-PRENATAL samples to: LifeLabs · Attn CDS Department • 100 International Boulevard• Toronto ON• M9W6J6 TEST REQUESTED LL TR # / CML TC# □ Genetic Test - Blood Sample 2 x 4mL EDTA 4005 □ Genetic Test (Pediatric) - Blood Sample 1 x 2mL EDTA 4008 □ Genetic Test - Other Sample Type 4014 PRENATAL SAMPLES: Please ship directly to CENTOGENE. Date Blood Collected (YYYY/MM/DD): ___________ Time Blood Collected (HH:MM)) :________ Collector Name: ___________________ GENETIC TESTING CONSENT I understand that a DNA specimen will be sent to LifeLabs for genetic testing. My physician has told me about the condition(s) being tested and its genetic basis. I am aware that correct information about the relationships between my family members is important. I agree that my specimen and personal health information may be sent to Centogene AG at their lab in Germany (address below). To ensure accurate testing, I agree that the results of any genetic testing that I have had previously completed by Centogene AG may be shared with LifeLabs.
    [Show full text]
  • Mackenzie's Mission Gene & Condition List
    Mackenzie’s Mission Gene & Condition List What conditions are being screened for in Mackenzie’s Mission? Genetic carrier screening offered through this research study has been carefully developed. It is focused on providing people with information about their chance of having children with a severe genetic condition occurring in childhood. The screening is designed to provide genetic information that is relevant and useful, and to minimise uncertain and unclear information. How the conditions and genes are selected The Mackenzie’s Mission reproductive genetic carrier screen currently includes approximately 1300 genes which are associated with about 750 conditions. The reason there are fewer conditions than genes is that some genetic conditions can be caused by changes in more than one gene. The gene list is reviewed regularly. To select the conditions and genes to be screened, a committee comprised of experts in genetics and screening was established including: clinical geneticists, genetic scientists, a genetic pathologist, genetic counsellors, an ethicist and a parent of a child with a genetic condition. The following criteria were developed and are used to select the genes to be included: • Screening the gene is technically possible using currently available technology • The gene is known to cause a genetic condition • The condition affects people in childhood • The condition has a serious impact on a person’s quality of life and/or is life-limiting o For many of the conditions there is no treatment or the treatment is very burdensome for the child and their family. For some conditions very early diagnosis and treatment can make a difference for the child.
    [Show full text]
  • Psykisk Utviklingshemming Og Forsinket Utvikling
    Psykisk utviklingshemming og forsinket utvikling Genpanel, versjon v03 Tabellen er sortert på gennavn (HGNC gensymbol) Navn på gen er iht. HGNC >x10 Andel av genet som har blitt lest med tilfredstillende kvalitet flere enn 10 ganger under sekvensering x10 er forventet dekning; faktisk dekning vil variere. Gen Gen (HGNC Transkript >10x Fenotype (symbol) ID) AAAS 13666 NM_015665.5 100% Achalasia-addisonianism-alacrimia syndrome OMIM AARS 20 NM_001605.2 100% Charcot-Marie-Tooth disease, axonal, type 2N OMIM Epileptic encephalopathy, early infantile, 29 OMIM AASS 17366 NM_005763.3 100% Hyperlysinemia OMIM Saccharopinuria OMIM ABCB11 42 NM_003742.2 100% Cholestasis, benign recurrent intrahepatic, 2 OMIM Cholestasis, progressive familial intrahepatic 2 OMIM ABCB7 48 NM_004299.5 100% Anemia, sideroblastic, with ataxia OMIM ABCC6 57 NM_001171.5 93% Arterial calcification, generalized, of infancy, 2 OMIM Pseudoxanthoma elasticum OMIM Pseudoxanthoma elasticum, forme fruste OMIM ABCC9 60 NM_005691.3 100% Hypertrichotic osteochondrodysplasia OMIM ABCD1 61 NM_000033.3 77% Adrenoleukodystrophy OMIM Adrenomyeloneuropathy, adult OMIM ABCD4 68 NM_005050.3 100% Methylmalonic aciduria and homocystinuria, cblJ type OMIM ABHD5 21396 NM_016006.4 100% Chanarin-Dorfman syndrome OMIM ACAD9 21497 NM_014049.4 99% Mitochondrial complex I deficiency due to ACAD9 deficiency OMIM ACADM 89 NM_000016.5 100% Acyl-CoA dehydrogenase, medium chain, deficiency of OMIM ACADS 90 NM_000017.3 100% Acyl-CoA dehydrogenase, short-chain, deficiency of OMIM ACADVL 92 NM_000018.3 100% VLCAD
    [Show full text]
  • By Submitted in Partial Satisfaction of the Requirements for Degree of in in the GRADUATE DIVISION of the UNIVERSITY of CALIFORN
    DDX3X and C12ORF57/Camkinin: Insight into the function and malfunction of two genes implicated in agenesis of the corpus callosum by Ruiji Jiang DISSERTATION Submitted in partial satisfaction of the requirements for degree of DOCTOR OF PHILOSOPHY in Biomedical Sciences in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Approved: ______________________________________________________________________________Aimee Kao Chair ______________________________________________________________________________Elliott Sherr ______________________________________________________________________________John Rubenstein ______________________________________________________________________________Kevin Shannon ______________________________________________________________________________ Committee Members ii Acknowledgements I would like to thank Malek Chouchane and Erik Ullian for their assistance in planning and collecting the electrophysiology data for the sections dealing with C12ORF57. The Linda Richards lab at the Queensland Brain Insitute, specifically Ching Moey and also provided valuable support in performing dual stain in situs and immunohistochemistry for the cell type specific expression assays as well as sectioning for mouse brains. Thanks to Suling Wong for her artistic expertise in illustrating our C12ORF57/Camkinin model Stephen Floor and the Doudna lab at Berkeley provided invaluable assistance in explaining the principles of the DDX3X unwinding assay, as well as providing technical assistance in purifying protein,
    [Show full text]
  • The University of Chicago Genetic Services Laboratories
    The University of Chicago Genetic Services Laboratories 5841 South Maryland Avenue, Room G701/MC0077, Chicago, IL 60637 Toll Free: 888.824.3637 | Local: 773.834.0555 | Fax: 773-702-9130 [email protected] | dnatesting.uchicago.edu | CLIA#: 14D0917593 | CAP#: 18827-49 QUICK GUIDE TO GENETIC TESTING TEST DISORDER CPT TAT COST Aceruloplasminemia testing CP sequencing 81406 4 weeks $2,200 Aceruloplasminemia CP deletion/duplication 81405 4 weeks $1,000 Albinism testing Albinism Sequencing Panel (20 genes sequencing)** 81407 8 weeks $3,500 Albinism Deletion/Duplication Panel (20 genes deletion/duplication analysis) 81407 6 weeks $2,500 Alstrom syndrome testing ALMS1 sequencing 81406 4 weeks $1,700 Alstrom syndrome ALMS1 deletion/duplication 81405 4 weeks $1,000 Alternating Hemiplegia of Childhood testing ATP1A3 sequencing Alternating hemiplegia of childhood 81406 4 weeks $2,025 Angelman syndrome MS-MLPA (detects methylation and deletions in 15q11- 81331 4 weeks $525 13) UPD 15 testing (requires samples from both parents 81402 4 weeks $540 also) Angelman syndrome Imprinting center deletion analysis 81403 4 weeks $450 UBE3A sequencing 81406 4 weeks $1,500 UBE3A deletion/duplication 81405 4 weeks $1,000 SLC9A6 sequencing 81406 4 weeks $1,500 X-linked Angelman-like syndrome SLC9A6 deletion/duplication 81405 4 weeks $1,000 Angelman Syndrome Tier 2 Panel ( MECP2,TCF4, SLC9A6 and UBE3A sequencing and 81479 4 weeks $4,400 deletion/duplication) Rett/Angelman Syndrome Sequencing Panel (21 genes sequencing)** 81407 8 weeks $4,400 Rett/Angelman
    [Show full text]
  • Gen- Symbol Genname Erkrankung(En) OMIM Gengröße
    Gen‐ Gengröße Genname Erkrankung(en) OMIM symbol (kb) Arterial calcification, generalized, of infancy, 2 614473 ABCC6 ATP‐BINDING CASSETTE, SUBFAMILY C, MEMBER 6 Pseudoxanthoma elasticum 264800 4,5 Pseudoxanthoma elasticum, forme fruste 177850 ACSL4 ACYL‐CoA SYNTHETASE LONG CHAIN FAMILY, MEMBER 4 Mental retardation, X‐linked 63 300387 2,1 AFF2 AF4/FMR2 FAMILY, MEMBER 2 (FMR2) Mental retardation, X‐linked, FRAXE type 309548 3,9 APOPTOSIS‐INDUCING FACTOR, MITOCHONDRION‐ASSOCIATED, 1 Combined oxidative phosphorylation deficiency 6 300816 AIFM1 1,8 (PDCD8) Cowchock syndrome 310490 Proteus syndrome, somatic 176920 AKT1 V‐AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 1 1,4 Cowden syndrome 6 615109 Megalencephaly‐polymicrogyria‐polydactyly‐hydrocephalus AKT3 V‐AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 3 (PKBG) 615937 1,4 syndrome 2 AP1S2 ADAPTOR‐RELATED PROTEIN COMPLEX 1, SIGMA‐2 SUBUNIT Mental retardation, X‐linked syndromic 5 304340 0,5 ARHGEF6 RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 6 (PIXA) Mental retardation, X‐linked 46 300436 2,3 ARHGEF9 RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 9 (PEM2) Epileptic encephalopathy, early infantile, 8 300607 1,6 ARID1A AT‐RICH INTERACTION DOMAIN‐CONTAINING PROTEIN 1A (SMARCF1) Coffin‐Siris syndrome 2 614607 6,9 ARID1B AT‐RICH INTERACTION DOMAIN‐CONTAINING PROTEIN 1B Coffin‐Siris syndrome 1 135900 6,7 Epileptic encephalopathy, early infantile, 1 308350 Hydranencephaly with abnormal genitalia 300215 Lissencephaly, X‐linked 2 300215 ARX ARISTALESS‐RELATED HOMEOBOX, X‐LINKED 1,7 Mental retardation, X‐linked 29 and others
    [Show full text]
  • Inheritest 500 PLUS
    Inheritest® 500 PLUS 525 genes Specimen ID: 00000000010 Container ID: H0651 Control ID: Acct #: LCA-BN Phone: SAMPLE REPORT, F-630049 Patient Details Specimen Details Physician Details DOB: 01/01/1991 Date Collected: 08/05/2019 12:00 (Local) Ordering: Age (yyy/mm/dd): 028/07/04 Date Received: 08/06/2019 Referring: Gender: Female Date Entered: 08/06/2019 ID: Patient ID: 00000000010 Date Reported: 08/21/2019 15:29 (Local) NPI: Ethnicity: Unknown Specimen Type: Blood Lab ID: MNEGA Indication: Carrier screening Genetic Counselor: None SUMMARY: POSITIVE POSITIVE RESULTS DISORDER (GENE) RESULTS INTERPRETATION Spinal muscular atrophy AT RISK AT RISK to be a silent carrier (2+0). For ethnic-specific risk (SMN1) 2 copies of SMN1; positive for revisions see Methods/Limitations. Genetic counseling is NMID: NM_000344 c.*3+80T>G SNP recommended. Risk: AT INCREASED RISK FOR AFFECTED PREGNANCY. See Additional Clinical Information. NEGATIVE RESULTS DISORDER (GENE) RESULTS INTERPRETATION Cystic fibrosis NEGATIVE This result reduces, but does not eliminate the risk to be a (CFTR) carrier. NMID: NM_000492 Risk: NOT at an increased risk for an affected pregnancy. Fragile X syndrome NEGATIVE: Not a carrier of a fragile X expansion. (FMR1) 29 and 36 repeats NMID: NM_002024 Risk: NOT at an increased risk for an affected pregnancy. ALL OTHER DISORDERS NEGATIVE This result reduces, but does not eliminate the risk to be a carrier. Risk: The individual is NOT at an increased risk for having a pregnancy that is affected with one of the disorders covered by this test. For partner's gene-specific risks, visit www.integratedgenetics.com.
    [Show full text]